These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 576165)

  • 21. Optimum age of measles immunization--maternal and transplacentally transmitted measles antibodies in infancy.
    Mohan M; Mehta PK; Sehgal S; Prabhakar AK; Bhargava SK
    Indian Pediatr; 1981 Sep; 18(9):631-5. PubMed ID: 7319611
    [No Abstract]   [Full Text] [Related]  

  • 22. Age of measles immunization in tropics.
    Mirchamsy H; Shafyi A; Mahinpour M; Nazari P
    Dev Biol Stand; 1978; 41():191-4. PubMed ID: 572788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection.
    Brunell PA; Vimal V; Sandu M; Courville TM; Daar E; Israele V
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):540-8. PubMed ID: 8548333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles in Tanzania: antibody response in children after vaccination and antibody state of mothers and newborns.
    de Haas PW; Masurel N; Anker WJ
    Trans R Soc Trop Med Hyg; 1983; 77(2):267-70. PubMed ID: 6868109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses.
    Halsey NA; Boulos R; Mode F; Andre J; Bowman L; Yaeger RG; Toureau S; Rohde J; Boulos C
    N Engl J Med; 1985 Aug; 313(9):544-9. PubMed ID: 4022091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measles antibody in previously immunized children. The need for revaccination.
    Linnemann CC; Dine MS; Bloom JE; Schiff GM
    Am J Dis Child; 1972 Jul; 124(1):53-7. PubMed ID: 5033750
    [No Abstract]   [Full Text] [Related]  

  • 28. Measles outbreak in Ibadan: clinical, serological and virological identification of affected children in selected hospitals.
    Adu FD; Ikusika A; Omotade O
    J Infect; 1997 Nov; 35(3):241-5. PubMed ID: 9459395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A study on measles immune status by ELISA].
    Li GQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 1989 Apr; 10(2):105-8. PubMed ID: 2736614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Fourth report to the medical research council by the measles sub-committee of the committee on development of vaccines and immunisation procedures.
    Lancet; 1977 Sep; 2(8038):571-5. PubMed ID: 71396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Measles morbidity among children inoculated against this infection].
    Bolotovskiĭ VM; Gelikman BG; Mikheev IV; Titova NS; Kikosh GV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):38-43. PubMed ID: 3705811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of measles vaccination in young malnourished African children].
    Monjour L; Bourdillon F; Froment A; Claudio-Ribeiro D; Fabre M; Chastang C; Gentilini M
    Bull Soc Pathol Exot Filiales; 1984; 77(3):271-7. PubMed ID: 6488419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.
    Dai B; Chen ZH; Liu QC; Wu T; Guo CY; Wang XZ; Fang HH; Xiang YZ
    Bull World Health Organ; 1991; 69(4):415-23. PubMed ID: 1934235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An assessment of the effectiveness of the measles immunization programme in Lagos, Nigeria.
    Ogunmekan DA; Bracken P; Marshall WC
    Ann Trop Med Parasitol; 1981 Feb; 75(1):87-92. PubMed ID: 7271359
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of placentally transmitted antibodies for measles in infants 3 to 11 months old in an urban slum community.
    Deivanayagam N; Vasudevan S; Krishnamurthy PV; Shankar VJ; Ashok TP; Nedunchelian K; Mala N; Ahmed SS
    Indian Pediatr; 1990 Sep; 27(9):919-23. PubMed ID: 2286435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroconversion following measles immunisation.
    Swami SS; Chandra S; Dudani IU
    J Commun Dis; 1987 Jun; 19(2):141-5. PubMed ID: 3454353
    [No Abstract]   [Full Text] [Related]  

  • 37. Measles reimmunization in children immunized before 1 year of age.
    Lampe RM; Weir MR; Scott RM; Weeks JL
    Am J Dis Child; 1985 Jan; 139(1):33-5. PubMed ID: 3969979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elimination of maternal antibodies against measles (is the policy of vaccinating children younger than nine months of age suitable for Turkey?).
    Kanra G; Ceyhan M
    Turk J Pediatr; 1991; 33(4):217-20. PubMed ID: 1814038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA; Harry TO
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of measles-rubella vaccination for mothers in early puerperal phase.
    Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K
    Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.